Although chemotherapy is under investigation as neoadjuvant and adjuvant strategy in early
stages, and some progress has been achieved in the treatment of locally advanced and …

Small cell lung cancer and targeted therapies : Current Opinion in Oncology Small cell lung
cancer and targeted therapies : Current Opinion in Oncology Log in or Register Subscribe to …

Lung cancer is the leading world-wide cause of cancer death. Small-cell lung cancer
(SCLC) accounts for 20–25% of lung carcinomas. Chemotherapy is the cornerstone of …

Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring
extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel …

Small cell lung cancer (SCLC) is a highly aggressive cancer usually with distal metastasis
and very poor prognosis. Chemotherapy is the treatment of choice for SCLC in all stages …

Small cell lung cancer (SCLC) accounts for 15% of lung cancer cases and is associated with
a dismal prognosis. Standard therapeutic regimens have been improved over the past …

Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis. It can be
very sensitive to radiation and cytotoxic chemotherapy and is potentially curable if all sites of …

Treatment of patients with inoperable locally advanced non small-cell lung cancer (NSCLC)
remains disappointing with less of 5% of patients alive at 5 years. Both initial local control …

Small-cell lung cancer (SCLC) is a rapidly progressing tumor in which chemotherapy has a
limited impact on survival. Unfortunately, little progress has been made in the medical …

Small cell lung cancer (SCLC) is an aggressive form of lung cancer that is characterized by
a rapid doubling time, early onset of dissemination and high sensitivity to chemotherapy …